{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026002","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2023-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.079438+00:00","generated_at":"2026-06-12T23:30:19.018875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Balchem Q2 sales $231.3M (-2.3% YoY); adjusted EPS $1.06; record EBITDA","bullets":["Q2 net sales $231.3M, down 2.3% YoY; GAAP net earnings $30.1M ($0.93 EPS).","Record quarterly adjusted EBITDA $59.1M, up 4.6% YoY; adjusted EPS $1.06 (vs $1.07 prior year).","Operating cash flow $35.0M; free cash flow $31.7M; repaid $26M revolving debt, net debt $338.7M.","Leverage ratio 1.5x net debt; completed new Vitacholine manufacturing unit for choline production.","Effective tax rate declined to 21.6% from 24.1% (255 bps lower)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026002","json":"https://secwatch.observer/filing/0001628280-23-026002.json","markdown":"https://secwatch.observer/filing/0001628280-23-026002.md","text":"https://secwatch.observer/filing/0001628280-23-026002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828023026002/0001628280-23-026002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828023026002/bcpc-20230728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:30:19.018875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7f7615772312cf7878f0c832f279fd804f0b242","claim":"BALCHEM CORP reported the quarter ended June 30, 2023 results: revenue $231.3 million, net income $30.1 million, EPS $0.93.","evidence_excerpt":"• Second quarter net sales were $231.3 million, a decrease of $5.4 million, or 2.3%, compared to the prior year. • Record quarterly adjusted EBITDA was $59.1 million, an increase of $2.6 million, or 4.6%, from the prior year. • GAAP net earnings were $30.1 million, an increase of $0.3 million, or 1.1% from the prior year. These net earnings resulted in GAAP earnings per share of $0.93.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/9326/000162828023026002/0001628280-23-026002-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$231.3 million"},{"label":"Net income","value":"$30.1 million"},{"label":"EPS","value":"$0.93"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}